Pfizer has decided to exercise its options under a previously-announced research and licensing agreement with Cytos Biotechnology AG of Switzerland, giving it exclusive rights to develop, manufacture and commercialise a group of novel vaccines. The decision has triggered an undisclosed payment to Cytos. The total value of the agreement, including milestones and technology transfer fees, is estimated at CHF 150 million.
